Table 4:
Ongoing clinical trials of selective jakinibs
| Agent | Specificity | Disease |
|---|---|---|
| Upadacitinib | JAK1 |
AD: NCT03569293, NCT03738397, NCT03568318, NCT03661138, NCT04195698, NCT03607422, NCT04666675 Hiradenitis Suppurativa: NCT04430855 Spondyloarthritis: NCT04169373 PsA: NCT03104374, NCT03104400 AS: NCT03178487 SLE: NCT03978520, NCT04451772 UC: NCT03653026, NCT03006068, NCT02819635, CD: NCT03345836, NCT03345823, NCT02782663, NCT02365649 Takayasu Arteritis: NCT04161898 Giant Cell Arteritis: NCT03725202 |
| Filgotinib | JAK1 |
RA: NCT02065700, NCT03025308 PsA: NCT03320876, NCT04115839, NCT04115748 CD: NCT02914600, NCT02914561, NCT03077412 AS: NCT04483700, NCT04483687 UC: NCT02914535 IBD: NCT03201445 Noninfectious Uveitis: NCT03207815 |
| Abrocitinib | JAK1 | AD: NCT04345367, NCT03422822, NCT03915496 |
| Itacitinib | JAK1 |
Acute GvHD:
NCT03846479 Chronic GvHD: NCT04200365, NCT03584516, NCT04446182 Prophylaxis for GvHD and Immune Effector Cell Therapy (Prevention of Cytokine Release Syndrome): NCT04071366, NCT04339101 Asthma: NCT04129931 MPN/Myelofibrosis: NCT04640025, NCT03144687, NCT01633372, NCT04629508 Non-Small Cell Lung Cancer: NCT03425006, NCT02917993 |
| ARQ-252 | JAK1 | Hand Eczema: NCT04378569 |
| BMS-986165 | TYK2 |
SLE: NCT03252587, NCT03920267 Lupus Nephritis: NCT03943147 CD: NCT03599622 UC: NCT03934216, NCT04613518 PsA: NCT03881059 Plaque Psoriasis: NCT03624127, NCT03611751, NCT04167462 Psoriasis: NCT04036435, NCT03924427 |
| Brepocitinib (PF-06700841) |
TYK2/ JAK1 |
Psoriasis: NCT03850483 Acne Inversa: NCT04092452 Hidradenitis suppurativa: NCT04092452 NSV: NCT03715829 PsA: NCT03963401 SLE: NCT03845517 CD: NCT03395184 UC: NCT02958865 |
| Ritlecitinib | JAK3/Tec kinases |
RA: NCT02969044 CD: NCT03395184 UC: NCT02958865 NSV: NCT03715829 AA: NCT03732807, NCT04006457, NCT04517864 |
| Cerdulatinib* | JAK1/JAK2/Syk | Vitiligo: NCT04103060 |
| Momelotinib | JAK1/JAK2/ACVR1 | MPN: NCT04173494 |
| Pacritinib* | JAK2/IRAK1 |
GvHD:
NCT02891603 MPN: NCT03645824, NCT03165734 Covid-19: NCT04404361 |
| Gusacitinib* (ASN002) | JAK1/JAK2/JAK3/TYK2/Syk |
Chronic Hand Dermatitis:
NCT03728504 AD: NCT03531957 |
*
Trials for cancer and/or malignancies have been excluded
AA, alopecia areata; AD, atopic dermatitis; AS, ankylosing spondylitis; CD, Crohn’s Disease; GvHD, graft-versus-host disease; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; MPN, myeloproliferative neoplasms; NSV, non-segmental vitiligo; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis